Generation and function of reactive oxygen species in dendritic cells during antigen presentation

Journal of Immunology

Volumn 171, Issue 6, 2003, Pages 3010-3018

  Matsue, Hiroyuki ^a   Edelbaum, Dale ^a   Shalhevet, David ^a   Mizumoto, Norikatsu ^a   Yang, Chendong ^a   Mummert, Mark E ^a   Oeda, Junichi ^b   Masayasu, Hiroyuki ^b   Takashima, Akira ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CROTON OIL; CYTOKINE; EBSELEN; GLUTAREDOXIN; OVALBUMIN; OXAZOLONE; REACTIVE OXYGEN METABOLITE; THIOREDOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CELL COMMUNICATION; CELL PROLIFERATION; CONTACT ALLERGY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; IMMUNOPATHOLOGY; MOUSE; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 0042834309     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.6.3010     Document Type: Article

References (63)

1. Droge, W. 2002. Free radicals in the physiological control of cell function. Physiol. Rev. 82:47.
2. Reth, M. 2002. Hydrogen peroxide as second messenger in lymphocyte activation. Nat. Immunol. 3:1129.
3. Sekkat, C., J. Dornand, and M. Gerber. 1988. Oxidative phenomena are implicated in human T-cell stimulation. Immunology 63:431.
4. Williams, M. S., and P. A. Henkart. 1996. Role of reactive oxygen intermediates in TCR-induced death of T cell blasts and hybridomas. J. Immunol. 157:2395.
5. Los, M., H. Schenk, K. Hexel, P. A. Baeuerle, W. Droge, and K. Schulze-Osthoff. 1995. IL-2 gene expression and NF-κB activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J. 14:3731.
6. Weber, G. F., S. Abromson-Leeman, and H. Cantor. 1995. A signaling pathway coupled to T cell receptor ligation by MMTV superantigen leading to transient activation and programmed cell death. Immunity 2:363.
7. Hildeman, D. A., T. Mitchell, T. K. Teague, P. Henson, B. J. Day, J. Kappler, and P. C. Marrack. 1999. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 10:735.
8. Devadas, S., L. Zaritskaya, S. G. Rhee, L. Oberley, and M. S. Williams. 2002. Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and Fas ligand expression. J. Exp. Med. 195:59.
9. Iwata, S., T. Hori, N. Sato, Y. Ueda-Taniguchi, T. Yamabe, H. Nakamura, H. Masutani, and J. Yodoi. 1994. Thiol-mediated redox regulation of lymphocyte proliferation: possible involvement of adult T cell leukemia-derived factor and glutathione in transferrin receptor expression. J. Immunol. 152:5633.
10. Nakashima, I., H. Suzuki, M. Kato, and A. A. Akhand. 2002. Redox control of T-cell death. Antioxid. Redox Signal. 4:353.
11. Abate, C., L. Patel, F. J. Rauscher, III, and T. Curran. 1990. Redox regulation of Fos and Jun DNA-binding activity in vitro. Science 249:1157.
12. Hirota, K., M. Matsui, S. Iwata, A. Nishiyama, K. Mori, and J. Yodoi, 1997. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA 94:3633.
13. Hayashi, T., Y. Ueno, and T. Okamoto. 1993. Oxidoreductive regulation of nuclear factor kB: involvement of a cellular reducing catalyst thioredoxin. J. Biol. Chem. 268:11380.
14. Schenk, H., M. Klein, W. Erdbrugger, W. Droge, and K. Schulze-Osthoff. 1994. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-κB and AP-1. Proc. Natl. Acad. Sci. USA 91:1672.
15. 2. J. Biol. Chem. 273:32554.
16. Xu, D., I. I. Rovira, and T. Finkel. 2002. Oxidants painting the cysteine chapel: redox regulation of PTPs. Dev. Cell 2:251.
17. Barford, D., and B. G. Neel. 1998. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 6:249.
18. Meng, T. C., T. Fukada, and N. K. Tonks. 2002. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol. Cell. 9:387.
19. fyn tyrosine kinases in human lymphocytes. Blood 82:1212.
20. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
21. Angelini, G., S. Gardella, M. Ardy, M. R. Ciriolo, G. Filomeni, G. Di Trapani, F. Clarke, R. Sitia, and A. Rubartelli. 2002. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc. Natl. Acad. Sci. USA 99:1491.
22. Kitajima, T., K. Ariizumi, P. R. Bergstresser, and A. Takashima. 1995. T cell-dependent loss of proliferative responsiveness to colony-stimulating factor-1 by a murine epidermal-derived dendritic cell line, XS52. J. Immunol. 155:5190.
23. Kitajima, T., K. Ariizumi, M. Mohamadzadeh, D. Edelbaum, P. R. Bergstresser, and A. Takashima. 1995. T cell-dependent secretion of IL-1β by a dendritic cell line (XS52) derived from murine epidermis. J. Immunol. 155:3794.
24. Kitajima, T., G. Caceres-Dittmar, F. J. Tapia, J. Jester, P. R. Bergstresser, and A. Takashima. 1996. T cell-mediated terminal maturation of dendritic cells: loss of adhesive and phagocytotic capacities. J. Immunol. 157:2340.
25. Kitajima, T., K. Ariizumi, P. R. Bergstresser, and A. Takashima. 1996. A novel mechanism of glucocorticoid-induced immune suppression: the inhibition of T cell-mediated terminal maturation of a murine dendritic cell line. J. Clin. Invest. 98:142.
26. Matsue, H., C. Yang, K. Matsue, D. Edelbaum, M. E. Mummert, and A. Takashima. 2002. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J. Immunol. 169:3555.
27. Muller, A., E. Cadenas, P. Graf, and H. Sies. 1984. A novel biologically active seleno-organic compound-I: glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ51 (ebselen). Biochem. Pharmacol. 33:3235.
28. Zhao, R., H. Masayasu, and A. Holmgren. 2002. Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. Proc. Natl. Acad. Sci. USA 99:8579.
29. Zhao, R., and A. Holmgren. 2002. A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase. J. Biol. Chem. 277:39456.
30. Schewe, C., T. Schewe, and A. Wendel. 1994. Strong inhibition of mammalian lipoxygenases by the antiinflammatory seleno-organic compound ebselen in the absence of glutathione. Biochem. Pharmacol. 48:65.
31. Hattori, R., R. Inoue, K. Sase, H. Eizawa, K. Kosuga, T. Aoyama, H. Masayasu, C. Kawai, S. Sasayama, and Y. Yui. 1994. Preferential inhibition of inducible nitric oxide synthase by ebselen. Eur. J. Pharmacol. 267:R1.
32. Cotgreave, I. A., S. K. Duddy, G. E. Kass, D. Thompson, and P. Moldeus. 1989. Studies on the anti-inflammatory activity of ebselen: ebselen interferes with granulocyte oxidative burst by dual inhibition of NADPH oxidase and protein kinase C. Biochem. Pharmacol. 38:649.
33. low thymocytes in vivo. Science 250:1720.
34. Xu, S., K. Ariizumi, G. Caceres-Dittmar, D. Edelbaum, K. Hashimoto, P. R. Bergstresser, and A. Takashima. 1995. Successive generation of antigen-presenting, dendritic cell lines from murine epidermis. J. Immunol. 154:2697.
35. Takashima, A., D. Edelbaum, T. Kitajima, R. K. Shadduck, G. L. Gilmore, S. Xu, R. S. Taylor, P. R. Bergstresser, and K. Ariizumi. 1995. Colony-stimulating factor-1 secreted by fibroblasts promotes the growth of dendritic cell lines (XS series) derived from murine epidermis. J. Immunol. 154:5128.
36. Mummert, M. E., D. Mummert, D. Edelbaum, F. Hui, H. Matsue, and A. Takashima. 2002. Synthesis and surface expression of hyaluronan by dendritic cells and its potential role in antigen presentation. J. Immunol. 169:4322.
37. Randolph, D. A., C. J. L. Carruthers, S. J. Szabo, K. M. Murphy, and D. D. Chaplin. 1999. Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma. J. Immunol. 162:2375.
38. Matsue, H., K. Matsue, M. Walters, K. Okumura, H. Yagita, and A. Takashima. 1999. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected "killer" dendritic cells. Nat. Med. 5:930.
39. Kumamoto, T., E. K. Huang, H. J. Paek, A. Morita, H. Matsue, R. F. Valentini, and A. Takashima. 2002. Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nat. Biotechnol. 20:64.
40. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693.
41. Mummert, M. E., M. Mohamadzadeh, D. I. Mummert, N. Mizumoto, and A. Takashima. 2000. Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking. J. Exp. Med. 192:769.
42. Mizumoto, N., T. Kumamoto, S. C. Robson, J. Sévigny, H. Matsue, K. Enjyoji, and A. Takashima. 2002. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat. Med. 8:358.
43. Gao, J. X., and A. C. Issekutz. 1993. The effect of ebselen on polymorphonuclear leukocyte and lymphocyte migration to inflammatory reactions in rats. Immunopharmacology 25:239.
44. Gao, J. X., and A. C. Issekutz. 1993. The effect of ebselen on polymorphonuclear leukocyte migration to joints in rats with adjuvant arthritis. Int. J. Immunopharmacol. 15:793.
45. Haddad, E., K. McCluskie, M. A. Birrell, D. Dabrowski, M. Pecoraro, S. Underwood, B. Chen, G. T. De Sanctis, S. E. Webber, M. L. Foster, and M. G. Belvisi. 2002. Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation. J. Immunol. 169:974.
46. Bogdan, C. 2001. Nitric oxide and the immune response. Nat. Immunol. 2:907.
47. Shimohashi, N., M. Nakamuta, K. Uchimura, R. Sugimoto, H. Iwamoto, M. Enjoji, and H. Nawata. 2000. Selenoorganic compound, ebselen, inhibits nitric oxide and tumor necrosis factor-alpha production by the modulation of Jun-N-terminal kinase and the NF-κB signaling pathway in rat Kupffer cells. J. Cell. Biochem. 78:595.
48. Nakamura, Y., Q. Feng, T. Kumagai, K. Torikai, H. Ohigashi, T. Osawa, N. Noguchi, E. Niki, and K. Uchida. 2002. Ebselen, a glutathione peroxidase mimetic seleno-organic compound, as a multifunctional antioxidant. Implication for inflammation-associated carcinogenesis. J. Biol. Chem. 277:2687.
49. Tiegs, G., S. Kusters, G. Kunstle, H. Hentze, A. K. Kiemer, and A. Wendel. 1998. Ebselen protects mice against T cell-dependent, TNF-mediated apoptotic liver injury. J. Pharmacol. Exp. Ther. 287:1098.
50. Takasago, T., E. E. Peters, D. I. Graham, H. Masayasu, and I. M. Macrae. 1997. Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br. J. Pharmacol. 122:1251.
51. Namura, S., I. Nagata, S. Takami, H. Masayasu, and H. Kikuchi. 2001. Ebselen reduces cytochrome c release from mitochondria and subsequent DNA fragmentation after transient focal cerebral ischemia in mice. Stroke 32:1906.
52. Imai, H., H. Masayasu, D. Dewar, D. I. Graham, and I. M. Macrae. 2001. Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia. Stroke 32:2149.
53. Yamaguchi, T., K. Sano, K. Takakura, I. Saito, Y. Shinohara, T. Asano, and H. Yasuhara. 1998. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 29:12.
54. Saito, I., T. Asano, K. Sano, K. Takakura, H. Abe, T. Yoshimoto, H. Kikuchi, T. Ohta, and S. Ishibashi. 1998. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. Neurosurgery 42:269.
55. Kiani, A., A. Rao, and J. Aramburu. 2000. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 12:359.
56. 2+, calcineurin, and NF-AT. Cell 96:611.
57. Brazelton, T. R., and R. E. Morris. 1996. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr. Opin. Immunol. 8:710.
58. Sehgal, S. N. 1998. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 31:335.
59. Abraham, R. T., and G. J. Wiederrecht. 1996. Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14:483.
60. Abraham, R. T. 1998. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr. Opin. Immunol. 10:330.
61. Akerblom, I. E., E. P. Slater, M. Beato, J. D. Baxter, and P. L. Mellon. 1988. Negative regulation by glucocorticoids through interference with a cAMP responsive enhancer. Science 241:350.
62. Auphan, N., J. A. DiDonato, C. Rosette, A. Helmberg, and M. Karin. 1995. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270:286.
63. Scheinman, R. I., A. Gualberto, C. M. Jewell, J. A. Cidlowski, and A. S. Baldwin. Jr. 1995. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol. Cell. Biol. 15:943.